263 related articles for article (PubMed ID: 27570245)
1. Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment.
Hoover R; Marbury TC; Preston RA; Quintas M; Lawrence LE; Paulson SK; Luke DR; Cammarata SK
J Clin Pharmacol; 2017 Mar; 57(3):328-335. PubMed ID: 27570245
[TBL] [Abstract][Full Text] [Related]
2. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
[TBL] [Abstract][Full Text] [Related]
3. Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function.
Hoover RK; Alcorn H; Lawrence L; Paulson SK; Quintas M; Cammarata SK
J Clin Pharmacol; 2018 Apr; 58(4):514-521. PubMed ID: 29251785
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacokinetics of Sulfobutylether-β-Cyclodextrin in Patients With Varying Degrees of Renal Impairment.
Hoover RK; Alcorn H; Lawrence L; Paulson SK; Quintas M; Luke DR; Cammarata SK
J Clin Pharmacol; 2018 Jun; 58(6):814-822. PubMed ID: 29578585
[TBL] [Abstract][Full Text] [Related]
5. The Pharmacokinetics of the CYP3A Substrate Midazolam After Steady-state Dosing of Delafloxacin.
Paulson SK; Wood-Horrall RN; Hoover R; Quintas M; Lawrence LE; Cammarata SK
Clin Ther; 2017 Jun; 39(6):1182-1190. PubMed ID: 28495029
[TBL] [Abstract][Full Text] [Related]
6. Disposition, metabolism and mass balance of delafloxacin in healthy human volunteers following intravenous administration.
McEwen A; Lawrence L; Hoover R; Stevens L; Mair S; Ford G; Williams D; Wood S
Xenobiotica; 2015; 45(12):1054-62. PubMed ID: 25986539
[TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.
Grasela DM; Christofalo B; Kollia GD; Duncan G; Noveck R; Manning JA; LaCreta FP
Pharmacotherapy; 2000 Jun; 20(6 Pt 2):87S-94S. PubMed ID: 10850525
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment.
Halabi A; Maatouk H; Siegler KE; Faisst N; Hinrichsen H
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):290-6. PubMed ID: 27128835
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
[TBL] [Abstract][Full Text] [Related]
11. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects.
Flanagan S; Ong V; Marbury T; Jandourek A; Gandhi RG; Sandison T
Pharmacotherapy; 2024 Jun; 44(6):435-443. PubMed ID: 38840536
[TBL] [Abstract][Full Text] [Related]
13. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
[TBL] [Abstract][Full Text] [Related]
14. Asenapine pharmacokinetics in hepatic and renal impairment.
Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
[TBL] [Abstract][Full Text] [Related]
15. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
[TBL] [Abstract][Full Text] [Related]
16. Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age.
Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
Clin Ther; 2016 Jan; 38(1):39-52. PubMed ID: 26581327
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
Zhao Q; Iyer GR; Verhaeghe T; Truyen L
J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
[TBL] [Abstract][Full Text] [Related]
18. What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone.
Cho JC; Crotty MP; White BP; Worley MV
Pharmacotherapy; 2018 Jan; 38(1):108-121. PubMed ID: 29059465
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.
Thabit AK; Crandon JL; Nicolau DP
Int J Antimicrob Agents; 2016 Nov; 48(5):535-541. PubMed ID: 27742208
[TBL] [Abstract][Full Text] [Related]
20. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
